dallas semaglutide gi obstruction law firm attorney in semaglutide law firm in louisiana Navigating Semaglutide Litigation dallas semaglutide gi obstruction law – dallas semaglutide bowel obstruction law

Discontinuation and weight regain How often people stop the medication TRIUMPH-4 (n=445, 68 weeks, obesity with knee osteoarthritis): 18.2% on 12 mg, 12.2% on 9 mg, 4% on placebo 2 TRANSCEND-T2D-1 (n=537, 40 weeks, type 2 diabetes): 5.1% on 12 mg, 4.5% on 9 mg, 0% on placebo 3 Phase 2 (n=338, 48 weeks): 6 to 16% across doses, 1% on placebo 1 For comparison, Wegovys STEP-1 trial reported a discontinuation rate of around 7% due to side effects, and Mounjaros SURMOUNT-1 reported a similar rate

If early-phase trials show promise, pivotal phase 3 studies could begin within the next few years, potentially leading to regulatory submissions later in the decade

Similarly, the STEP trials examining semaglutide for weight management documented comparable rates of digestive complaints

It is smart periodization

Alam S, Giri PK